AIM™ platform: A new immunotherapy approach for viral diseases

Overview
This document describes the AIM platform's ability to enrich and expand antigen-specific CD8+ T cells for viral targets. G-Rex® culture systems were used for the 14-day expansion process.
What this paper found
AIM nanoparticles, which mimic dendritic cell function, enriched and expanded multi-antigen-specific CD8+ T cells against EBV, HTLV-1 and HPV from HLA-A*02:01 healthy-donor leukapheresis cells. CD8+ T cells were enriched on a CliniMACS Prodigy and expanded for 14 days in a G-Rex® culture system. Summed antigen-specific frequencies were 95.45% and 69.23% for EBV in two donors, and 46.69% and 17.64% for HTLV-1. Over 90% of expanded cells had memory phenotypes. EBV-specific cells were polyfunctional and killed peptide-pulsed target cells. In four NEXI-003 validation runs, cells were 96.82% ± 2.89% CD3+/CD4− and killed HPV-16- and HPV-18-positive HLA-A2 tumor lines, with no significant killing of autologous PBMCs.
Note: Preclinical study using healthy-donor cells restricted to HLA-A*02:01.
In summary, AIM technology represents a new scalable and cost-effective therapeutic platform that has the potential to cure viral diseases. — David Langan, Ruipeng Wang, Keshanti Tidwell, Selome Mitiku, Alison Farrell, Catrina Johnson, Adam Parks, Lauren Suarez, Shweta Jain, Sojung Kim, Kristi Jones, Mathias Oelke, Jerome Zeldis, Frontiers in Medicine
Study details
- Authors
- David Langan, Ruipeng Wang, Keshanti Tidwell, Selome Mitiku, Alison Farrell, Catrina Johnson, Adam Parks, Lauren Suarez, Shweta Jain, Sojung Kim, Kristi Jones, Mathias Oelke, Jerome Zeldis
- Institution
- NexImmune Inc., Gaithersburg, MD, United States
- Journal
- Frontiers in Medicine
- Year
- 2022
- Cell type(s)
- VST Cells
- Application area
- Infectious disease · Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
After CD4+ T cell depletion on day 0, CD8+ T cells were enriched on a CliniMACS Prodigy using AIM nanoparticles. The enriched cells were then seeded into a G-Rex® culture system and expanded for 14 days. Cells were collected on day 14 and frozen in liquid nitrogen until testing.
Explore related
Full citation
Langan D, Wang R, Tidwell K, et al. AIM™ platform: A new immunotherapy approach for viral diseases. Front Med (Lausanne). 2022;9:1070529.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.